Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Dow
US Department of Justice
AstraZeneca
Deloitte
Chubb
Farmers Insurance
Healthtrust
Federal Trade Commission

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021067

« Back to Dashboard

NDA 021067 describes ASMANEX TWISTHALER, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the ASMANEX TWISTHALER profile page.

The generic ingredient in ASMANEX TWISTHALER is mometasone furoate. There are twenty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Summary for 021067
Tradename:ASMANEX TWISTHALER
Applicant:Merck Sharp Dohme
Ingredient:mometasone furoate
Patents:2
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Formulation / Manufacturing:see details
Pharmacology for NDA: 021067
Medical Subject Heading (MeSH) Categories for 021067
Suppliers and Packaging for NDA: 021067
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067 NDA Merck Sharp & Dohme Corp. 0085-1341 N 0085-1341-01
ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067 NDA Merck Sharp & Dohme Corp. 0085-1341 N 0085-1341-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrength0.22MG/INH
Approval Date:Mar 30, 2005TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 17, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Sep 17, 2018Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrength0.11MG/INH
Approval Date:Feb 1, 2008TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 17, 2018Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021067

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-001 Mar 30, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme ASMANEX TWISTHALER mometasone furoate POWDER;INHALATION 021067-002 Feb 1, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Citi
Express Scripts
QuintilesIMS
Cerilliant
Teva
Harvard Business School
Fuji
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.